Literature DB >> 16841343

Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder.

Eric A Storch1, Michael J Larson, Nathan A Shapira, Herbert E Ward, Tanya K Murphy, Gary R Geffken, Holly Valerio, Wayne K Goodman.   

Abstract

Despite wide use, relatively little is known about sociodemographic and clinical characteristics that predict early fluoxetine response. What research has been conducted has produced inconsistent findings, which may be due to the statistical procedures used, and no studies to date have examined predictors of early fluoxetine treatment response. Sixty adults with obsessive-compulsive disorder (OCD) completed an open-label fluoxetine trial for 8 weeks (up to 40 mg) after a 1-week, single-blind, placebo run-in before baseline assessment. The baseline and posttreatment assessment battery included the Yale-Brown Obsessive Compulsive Scale, the Hamilton Rating Scale for Depression, and the Yale Global Tic Severity Scale. Patient characteristics included illness duration, age, age of onset, gender, and pharmacological treatment history. Independent t-tests and multiple logistic regression analysis showed that longer illness duration, older age, and greater symptom severity were associated with nonresponse. Our findings highlight the impact of functional psychiatric impairment on determining those who may respond to treatment. Furthermore, findings suggest early predictors of patients with certain characteristics who may ultimately need adjunctive care to facilitate response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841343     DOI: 10.1002/da.20197

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  10 in total

1.  Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods.

Authors:  Christina L Boisseau; Steven A Rasmussen
Journal:  Contemp Clin Trials       Date:  2018-01-03       Impact factor: 2.226

Review 2.  Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: an overview.

Authors:  S Esposito; S Bianchini; E Baggi; M Fattizzo; D Rigante
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-24       Impact factor: 3.267

3.  Intensive residential treatment for severe obsessive-compulsive disorder: characterizing treatment course and predictors of response.

Authors:  Brian P Brennan; Catherine Lee; Jason A Elias; Jesse M Crosby; Brittany M Mathes; Marie-Christine Andre; Christina M Gironda; Harrison G Pope; Michael A Jenike; Garrett M Fitzmaurice; James I Hudson
Journal:  J Psychiatr Res       Date:  2014-05-23       Impact factor: 4.791

Review 4.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 5.  Drug treatment of obsessive-compulsive disorder.

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

6.  Novel ensemble method for the prediction of response to fluvoxamine treatment of obsessive-compulsive disorder.

Authors:  Hesam Hasanpour; Ramak Ghavamizadeh Meibodi; Keivan Navi; Sareh Asadi
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-10       Impact factor: 2.570

7.  Do polygenic risk and stressful life events predict pharmacological treatment response in obsessive compulsive disorder? A gene-environment interaction approach.

Authors:  María Alemany-Navarro; Javier Costas; Eva Real; Cinto Segalàs; Sara Bertolín; Laura Domènech; Raquel Rabionet; Ángel Carracedo; Jose M Menchón; Pino Alonso
Journal:  Transl Psychiatry       Date:  2019-02-04       Impact factor: 6.222

8.  Response to Fluvoxamine in the Obsessive-Compulsive Disorder Patients: Bayesian Ordinal Quantile Regression.

Authors:  Samad Safiloo; Yadollah Mehrabi; Sareh Asadi; Soheila Khodakarim
Journal:  Clin Pract Epidemiol Ment Health       Date:  2021-10-15

9.  The Effects of Demographic Characteristics, Memory Deficits, and Executive Functioning Impairments in Failure to Respond to Fluvoxamine among Patients with Obsessive-Compulsive Disorder in Iran.

Authors:  Ali Nazeri Astaneh; Gita Sadighi; Neda Alibeigi; Parisa Abdollahzadeh; Bahareh Abdollahzadeh
Journal:  Med J Islam Repub Iran       Date:  2022-02-23

10.  New therapeutic approach to Tourette Syndrome in children based on a randomized placebo-controlled double-blind phase IV study of the effectiveness and safety of magnesium and vitamin B6.

Authors:  Rafael Garcia-Lopez; Emilio Perea-Milla; Cesar Ruiz Garcia; Francisco Rivas-Ruiz; Julio Romero-Gonzalez; Jose L Moreno; Vicente Faus; Guadalupe del Castillo Aguas; Juan C Ramos Diaz
Journal:  Trials       Date:  2009-03-10       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.